Bina Rawal continued:
"It is misleading to suggest that the pharmaceutical industry routinely withholds clinical trial data from doctors and researchers.
“In late 2013, an ABPI commissioned study was published in a peer reviewed journal. This study highlighted a positive trend of increasing levels of disclosure for industry-sponsored clinical trials, with almost nine out of ten of all industry-sponsored clinical trials disclosed by 31 January 2013¹. The research covers new medicines approved between 2009 - 2011, which includes trials conducted over the preceding 10 or more years – i.e. during the entire development program.
“However we recognise that there is still work to be done and we are continuing on a journey to achieving greater clinical trial transparency. The ABPI has made available a new clinical trial disclosure toolkit to assist companies and will continue to engage with key stakeholders on this issue.”
Notes to editor
¹The research shows that over three quarters (76%) of all industry-sponsored clinical trials for new medicines recently approved by the European Medicines Agency (EMA) had some results disclosed within a year of completion or of regulatory approval. Rates of disclosure have continued to rise and almost nine in ten (89%) of these trials had disclosed results by 31 January 2013.
About the ABPI
The ABPI represents innovative research-based biopharmaceutical companies, large, medium and small, leading an exciting new era of biosciences in the UK.
Our industry, a major contributor to the economy of the UK, brings life-saving and life-enhancing medicines to patients. Our members supply 90 per cent of all medicines used by the NHS, and are researching and developing over two-thirds of the current medicines pipeline, ensuring that the UK remains at the forefront of helping patients prevent and overcome diseases.
The ABPI is recognised by government as the industry body negotiating on behalf of the branded pharmaceutical industry, for statutory consultation requirements including the pricing scheme for medicines in the UK.
ABPI Press Office
Tel: +44 (0) 20 7747 1441
Mobile: +44 (0) 7850 312064